Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
May 17, 2007

Vernalis and Servier Research Group Ink Discovery Deal

  • Vernalis and Servier entered into a joint, three-year, oncology drug discovery collaboration. Under the terms of the collaboration, which utilizes Vernalis' drug discovery platform on an undisclosed target, Vernalis will receive an upfront payment and a share in the downstream success of the product.

    "The partnership with Vernalis is a major step in our strategy to increase our efforts in the development of novel anti-cancer therapeutic approaches," remarks Emmanuel Canet, M.D., Ph.D., vp Servier R&D. “This collaboration will expedite the discovery of innovative compounds with potential use in therapeutic indications with high unmet medical need.”



Be sure to take the GEN Poll

CRISPR Patent Controversy

Do you think recently released email from a former Broad Institute scientist to Jennifer Doudna will expedite a final legal decision on who owns the CRISPR patent?

More »